Abstract
Summary
According to our LPI (LP Information) latest study, the global Duchenne Muscular Dystrophy market size was valued at US$ 1176.8 million in 2023. With growing demand in downstream market, the Duchenne Muscular Dystrophy is forecast to a readjusted size of US$ 14870 million by 2030 with a CAGR of 43.7% during review period. _x000D_
The research report highlights the growth potential of the global Duchenne Muscular Dystrophy market. Duchenne Muscular Dystrophy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Duchenne Muscular Dystrophy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Duchenne Muscular Dystrophy market._x000D_
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20._x000D_
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc._x000D_
Key Features:_x000D_
The report on Duchenne Muscular Dystrophy market reflects various aspects and provide valuable insights into the industry._x000D_
Market Size and Growth: The research report provide an overview of the current size and growth of the Duchenne Muscular Dystrophy market. It may include historical data, market segmentation by Type (e.g., Exondys 51, Emflaza), and regional breakdowns._x000D_
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Duchenne Muscular Dystrophy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs._x000D_
Competitive Landscape: The research report provides analysis of the competitive landscape within the Duchenne Muscular Dystrophy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market._x000D_
Technological Developments: The research report can delve into the latest technological developments in the Duchenne Muscular Dystrophy industry. This include advancements in Duchenne Muscular Dystrophy technology, Duchenne Muscular Dystrophy new entrants, Duchenne Muscular Dystrophy new investment, and other innovations that are shaping the future of Duchenne Muscular Dystrophy._x000D_
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Duchenne Muscular Dystrophy market. It includes factors influencing customer ' purchasing decisions, preferences for Duchenne Muscular Dystrophy product._x000D_
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Duchenne Muscular Dystrophy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Duchenne Muscular Dystrophy market. The report also evaluates the effectiveness of these policies in driving market growth._x000D_
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Duchenne Muscular Dystrophy market. _x000D_
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Duchenne Muscular Dystrophy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments._x000D_
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Duchenne Muscular Dystrophy market._x000D_
Market Segmentation:_x000D_
Duchenne Muscular Dystrophy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value._x000D_
Segmentation by type_x000D_
Exondys 51_x000D_
Emflaza_x000D_
Translarna_x000D_
Segmentation by application_x000D_
Hospitals_x000D_
Clinics_x000D_
Home Care_x000D_
This report also splits the market by region:_x000D_
Americas_x000D_
United States_x000D_
Canada_x000D_
Mexico_x000D_
Brazil_x000D_
APAC_x000D_
China_x000D_
Japan_x000D_
Korea_x000D_
Southeast Asia_x000D_
India_x000D_
Australia_x000D_
Europe_x000D_
Germany_x000D_
France_x000D_
UK_x000D_
Italy_x000D_
Russia_x000D_
Middle East & Africa_x000D_
Egypt_x000D_
South Africa_x000D_
Israel_x000D_
Turkey_x000D_
GCC Countries_x000D_
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration._x000D_
Sarepta Therapeutics_x000D_
PTC Therapeutics_x000D_
Pfizer_x000D_
Bristol-Myers Squibb_x000D_
Italfarmaco_x000D_
Santhera Pharmaceuticals_x000D_
Key Questions Addressed in this Report_x000D_
What is the 10-year outlook for the global Duchenne Muscular Dystrophy market?_x000D_
What factors are driving Duchenne Muscular Dystrophy market growth, globally and by region?_x000D_
Which technologies are poised for the fastest growth by market and region?_x000D_
How do Duchenne Muscular Dystrophy market opportunities vary by end market size?_x000D_
How does Duchenne Muscular Dystrophy break out type, application?_x000D_
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Duchenne Muscular Dystrophy by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Duchenne Muscular Dystrophy by Country/Region, 2019, 2023 & 2030
2.2 Duchenne Muscular Dystrophy Segment by Type
2.2.1 Exondys 51
2.2.2 Emflaza
2.2.3 Translarna
2.3 Duchenne Muscular Dystrophy Sales by Type
2.3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2019-2024)
2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2019-2024)
2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2019-2024)
2.4 Duchenne Muscular Dystrophy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy Sales by Application
2.5.1 Global Duchenne Muscular Dystrophy Sale Market Share by Application (2019-2024)
2.5.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Application (2019-2024)
2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Application (2019-2024)
3 Global Duchenne Muscular Dystrophy by Company
3.1 Global Duchenne Muscular Dystrophy Breakdown Data by Company
3.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Company (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Company (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Annual Revenue by Company (2019-2024)
3.2.1 Global Duchenne Muscular Dystrophy Revenue by Company (2019-2024)
3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2019-2024)
3.3 Global Duchenne Muscular Dystrophy Sale Price by Company
3.4 Key Manufacturers Duchenne Muscular Dystrophy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Duchenne Muscular Dystrophy Product Location Distribution
3.4.2 Players Duchenne Muscular Dystrophy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Duchenne Muscular Dystrophy by Geographic Region
4.1 World Historic Duchenne Muscular Dystrophy Market Size by Geographic Region (2019-2024)
4.1.1 Global Duchenne Muscular Dystrophy Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Duchenne Muscular Dystrophy Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Duchenne Muscular Dystrophy Market Size by Country/Region (2019-2024)
4.2.1 Global Duchenne Muscular Dystrophy Annual Sales by Country/Region (2019-2024)
4.2.2 Global Duchenne Muscular Dystrophy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Duchenne Muscular Dystrophy Sales Growth
4.4 APAC Duchenne Muscular Dystrophy Sales Growth
4.5 Europe Duchenne Muscular Dystrophy Sales Growth
4.6 Middle East & Africa Duchenne Muscular Dystrophy Sales Growth
5 Americas
5.1 Americas Duchenne Muscular Dystrophy Sales by Country
5.1.1 Americas Duchenne Muscular Dystrophy Sales by Country (2019-2024)
5.1.2 Americas Duchenne Muscular Dystrophy Revenue by Country (2019-2024)
5.2 Americas Duchenne Muscular Dystrophy Sales by Type
5.3 Americas Duchenne Muscular Dystrophy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Sales by Region
6.1.1 APAC Duchenne Muscular Dystrophy Sales by Region (2019-2024)
6.1.2 APAC Duchenne Muscular Dystrophy Revenue by Region (2019-2024)
6.2 APAC Duchenne Muscular Dystrophy Sales by Type
6.3 APAC Duchenne Muscular Dystrophy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Duchenne Muscular Dystrophy by Country
7.1.1 Europe Duchenne Muscular Dystrophy Sales by Country (2019-2024)
7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2019-2024)
7.2 Europe Duchenne Muscular Dystrophy Sales by Type
7.3 Europe Duchenne Muscular Dystrophy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Duchenne Muscular Dystrophy by Country
8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Sales by Country (2019-2024)
8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Revenue by Country (2019-2024)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Sales by Type
8.3 Middle East & Africa Duchenne Muscular Dystrophy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy
10.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy
10.4 Industry Chain Structure of Duchenne Muscular Dystrophy
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Duchenne Muscular Dystrophy Distributors
11.3 Duchenne Muscular Dystrophy Customer
12 World Forecast Review for Duchenne Muscular Dystrophy by Geographic Region
12.1 Global Duchenne Muscular Dystrophy Market Size Forecast by Region
12.1.1 Global Duchenne Muscular Dystrophy Forecast by Region (2025-2030)
12.1.2 Global Duchenne Muscular Dystrophy Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Duchenne Muscular Dystrophy Forecast by Type
12.7 Global Duchenne Muscular Dystrophy Forecast by Application
13 Key Players Analysis
13.1 Sarepta Therapeutics
13.1.1 Sarepta Therapeutics Company Information
13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Sarepta Therapeutics Main Business Overview
13.1.5 Sarepta Therapeutics Latest Developments
13.2 PTC Therapeutics
13.2.1 PTC Therapeutics Company Information
13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 PTC Therapeutics Main Business Overview
13.2.5 PTC Therapeutics Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Italfarmaco
13.5.1 Italfarmaco Company Information
13.5.2 Italfarmaco Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Italfarmaco Main Business Overview
13.5.5 Italfarmaco Latest Developments
13.6 Santhera Pharmaceuticals
13.6.1 Santhera Pharmaceuticals Company Information
13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolios and Specifications
13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Santhera Pharmaceuticals Main Business Overview
13.6.5 Santhera Pharmaceuticals Latest Developments
14 Research Findings and Conclusion